Form 4: Natera Co-Founder Jonathan Sheena Sells Shares to Cover Tax Obligations and Under 10b5-1 Plan

Jonathan Sheena, co-founder of Natera, Inc., sold shares of common stock on March 5th and 6th, 2024, to cover tax obligations and under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jonathan Sheena, a co-founder of Natera, Inc., reported the sale of Natera common stock.
• On March 5, 2024, 1,028 shares were sold at a price of $88.365 per share.
• On March 6, 2024, 3,184 shares were sold at a weighted average price of $88.4533, with individual prices ranging from $87.99 to $88.97.
• An additional 1,816 shares were sold on March 6, 2024, at a weighted average price of $89.1282, with individual prices ranging from $89.03 to $89.19.
• These sales were conducted to satisfy tax withholding obligations related to the vesting of Restricted Stock Units and pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2022.
• Following these transactions, Sheena directly owns 458,585 shares of Natera common stock.
• Sheena also indirectly owns 14,655 shares through the Caraluna 1 Trust and 14,655 shares through the Caraluna 2 Trust, both held for the benefit of minor children, for which he disclaims beneficial ownership.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports stock sales for tax purposes and under a pre-existing trading plan, which is a routine activity. There's no indication of positive or negative implications for the company's performance.

Industry Context

Insider sales are a common occurrence, especially when related to tax obligations or pre-planned trading arrangements like Rule 10b5-1 plans. These sales can sometimes create short-term price pressure but are often viewed in the context of the individual's overall holdings and financial planning.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the biotech and diagnostics sectors like Natera, to utilize Rule 10b5-1 trading plans to diversify their holdings or manage tax liabilities.
• Comparable companies such as Exact Sciences or Guardant Health also see insider trading activity, often related to similar circumstances.
• The size of the transactions is relatively small compared to the overall market capitalization of Natera, suggesting it's unlikely to have a significant long-term impact.

Stakeholder Impact

• The stock sales could have a minor, temporary impact on shareholders due to potential price fluctuations.
• The sales do not directly impact employees, customers, suppliers, or creditors.

Key Dates